Interestingly, Tiraboschi and colleagues found that low dose docetaxel treatment inhibits Gal-3 expression in prostate cancer cells, leading to a reconditioned TME and a superior response to tumour vaccination in a post-surgery mouse model (164). Here, LGALS3 is linked to prostate cancer.